Drug Profile
Zidovudine - Mylan Pharmaceuticals
Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Mylan Pharmaceuticals
- Class Antiretrovirals; Azides; Nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 12 Feb 2019 Zidovudine 100mg is not yet available for HIV-1 infections in USA